New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
17:33 EDTSCMP, TKPYYSucampo, Takeda say that Amitiza NDA will not be filed in second half of 2014
Sucampo Pharma Americas, a wholly owned subsidiary of Sucampo Pharmaceuticals (SCMP), and its development and commercialization partner's subsidiary Takeda Pharmaceuticals (TKPYY) announced that the New Drug Application, NDA, for the liquid formulation of Amitiza will not be filed in the second half of 2014. In preliminary pre-NDA meeting comments, the FDA informed Sucampo that it would require additional data to characterize pharmacokinetics of the new formulation. As a result of this outcome in conjunction with the FDA feedback, Sucampo and Takeda are now assessing next steps, which may include formulation modification.
News For SCMP;TKPYY From The Last 14 Days
Check below for free stories on SCMP;TKPYY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
09:06 EDTTKPYYTakeda unit granted orphan status for pancreatic cancer treatment
Millennium Pharmaceuticals' treatment of pancreatic cancer was granted FDA orphan designation, according to a post to the regulator's site. Reference Link
July 25, 2014
16:45 EDTSCMPS&R Foundation reports 6.3% stake in Sucampo
Subscribe for More Information
July 23, 2014
06:51 EDTSCMPSucampo announces publication of NICE recommendatoin for Amitiza
Sucampo announced that the United Kingdom's National Institute of Health and Care Excellence has published the technology appraisal guidance recommending the use of AMITIZA in the treatment of chronic idiopathic constipation and associated symptoms in adults who have failed laxatives. The NICE guidance recommends AMITIZA as an option for treating CIC for adults in whom treatment with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and for whom invasive treatment for constipation is being considered.
July 22, 2014
15:12 EDTSCMPSucampo says FDA approves addition of Nitto Medic as Rescula production site
Sucampo Pharmaceuticals disclosed in a regulatory filing that on July 15 the company received an approval letter from the FDA to its prior approval supplement in response to FDAs review of the revised Drug Master File of R-Tech Ueno. The approval provides for the addition of Nitto Medic of Toyama, Japan as a new production site for Rescula 0.15%. "The company has adequate supply of RESCULA to be able to supply the U.S. market into the first quarter of 2015," Sucampo added.
July 21, 2014
15:10 EDTTKPYYTakeda Pharmaceutical unit granted orphan status for gastric cancer treatment
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use